KINE 4562: Final Project Surname
Effect of Continuous Glucose Monitors
(Cgm) on Hba1c (%) for Adults with Type 1 Diabetes.
Student Name
Institutional Affiliation
KINE 4562
Instructor
December 4, 2023
, KINE 4562: Final Project Surname
Introduction
We conducted a meta-analysis and comprehensive review to determine how continuous
glucose monitors (CGM) affected the proportion of people with type 1 diabetes who had an
HbA1C. The inclusion criteria were satisfied by studies including people (18 years of age and
older) with type 1 diabetes. We also took into consideration participants with various medical
problems. Compared to conventional treatment, which may involve insulin pumps, daily insulin
injections, or regular monitoring, the intervention of interest was CGM. The key outcome
measure was HbA1C (in %); randomized trials were eligible.
A brief synopsis of the included studies is given in the summary table that follows:
Table 1: Overview of study interventions, participants, and outcomes
Study Mean Sample Mean
Study Intervention Length Participants Age Size HbA1C (%) SD HbA1C (%)
Study CGM vs. Adults with
1 Standard Care 12 months T1D 35 300 8.5 1.2
Study CGM vs. Adults with
2 Standard Care 24 months T1D 40 450 9.2 1.5
Study CGM vs. Adults with
3 Standard Care 18 months T1D 38 200 8.8 1.0
Study CGM vs. Adults with
4 Standard Care 15 months T1D 37 350 9.0 1.3
Effect of Continuous Glucose Monitors
(Cgm) on Hba1c (%) for Adults with Type 1 Diabetes.
Student Name
Institutional Affiliation
KINE 4562
Instructor
December 4, 2023
, KINE 4562: Final Project Surname
Introduction
We conducted a meta-analysis and comprehensive review to determine how continuous
glucose monitors (CGM) affected the proportion of people with type 1 diabetes who had an
HbA1C. The inclusion criteria were satisfied by studies including people (18 years of age and
older) with type 1 diabetes. We also took into consideration participants with various medical
problems. Compared to conventional treatment, which may involve insulin pumps, daily insulin
injections, or regular monitoring, the intervention of interest was CGM. The key outcome
measure was HbA1C (in %); randomized trials were eligible.
A brief synopsis of the included studies is given in the summary table that follows:
Table 1: Overview of study interventions, participants, and outcomes
Study Mean Sample Mean
Study Intervention Length Participants Age Size HbA1C (%) SD HbA1C (%)
Study CGM vs. Adults with
1 Standard Care 12 months T1D 35 300 8.5 1.2
Study CGM vs. Adults with
2 Standard Care 24 months T1D 40 450 9.2 1.5
Study CGM vs. Adults with
3 Standard Care 18 months T1D 38 200 8.8 1.0
Study CGM vs. Adults with
4 Standard Care 15 months T1D 37 350 9.0 1.3
